ArticleScientific reports2018
Beneficial effects of intravenous iron therapy in a rat model of heart failure with preserved systemic iron status but depleted intracellular cardiac stores.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Iron Deficiency in Acute Coronary Syndrome Treated with Percutaneous Angioplasty-A Factor of Unestablished Significance.Biomedicines · 2026Article
- Phase-dependent iron dysmetabolism in myocardial ischemia-reperfusion injury: From mechanisms to therapies.American heart journal plus : cardiology research and practice · 2025Review
- Prevalence and independent predictors of Iron deficiency in Yemeni patients with congestive heart failure: a retrospective cross-sectional study.Scientific reports · 2024Article
- Identification of three mechanistic pathways for iron-deficient heart failure.European heart journal · 2024Review
- A new effect of intravenous iron treatment in pregnancy: contraction in nonstress test and timing of labor.Revista da Associacao Medica Brasileira (1992) · 2024Article
- How can sodium-glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure.European journal of heart failure · 2022Review
- Appraising the Causal Association between Systemic Iron Status and Heart Failure Risk: A Mendelian Randomisation Study.Nutrients · 2022Article
- Article
- Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology.Journal of clinical medicine · 2021Review
- Safety and efficacy of iron supplementation after myocardial infarction in mice with moderate blood loss anaemia.ESC heart failure · 2021Article
- Iron Overload, Oxidative Stress, and Ferroptosis in the Failing Heart and Liver.Antioxidants (Basel, Switzerland) · 2021Review
- Ivabradine is as effective as metoprolol in the prevention of ventricular arrhythmias in acute non-reperfused myocardial infarction in the rat.Scientific reports · 2020Article
- Patterns of DNA variation between the autosomes, the X chromosome and the Y chromosome in Bos taurus genome.Scientific reports · 2020Article
- Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells.Journal of cellular and molecular medicine · 2020Article
- Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Iron deficiency (ID) commonly occurs in chronic heart failure (HF) and is associated with poor prognosis. Neither its causes nor pathophysiological significance are clearly understood. We aimed to assess iron status and the effect of iron supplementation in the rat model of post-myocardial infarction (MI) HF. Four weeks after induction of MI to induce HF or sham surgery, rats received intravenous iron (ferric carboxymaltose) or saline, 4 doses in 1-week intervals. HF alone did not cause anemia, systemic or myocardial ID, but reduced myocardial ferritin, suggesting depleted cardiomyocyte iron stores. Iron therapy increased serum Fe, ferritin and transferrin saturation as well as cardiac and hepatic iron content in HF rats, but did not increase myocardial ferritin. This was accompanied by: (1) better preservation of left ventricular (LV) ejection fraction and smaller LV dilation, (2) preservation of function of Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.